权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Assessment Of Patients With Borrelia Infection

疏螺旋体感染患者的评估

基本信息

批准号：
10927751
负责人：
ADRIANA R MARQUES
金额：
$ 99.87万
依托单位：
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10927751
关键词：
18 year old Address Adolescent Adult Aftercare Age Anaplasma phagocytophilum Annual Reports Antibiotic Therapy Antibiotics Area Arthralgia Babesia microti Biological Markers Borrelia Infections Borrelia burgdorferi Case Study Child Childhood Classification Clinical Protocols Clinical Research Country Data Development Diagnosis Enrollment Europe European Fatigue Frequencies Headache Health Heart Human Immune response Impairment Individual Infection Investigation Joints Lyme Disease Lyme disease diagnosis Memory Myalgia Names Neck Nervous System Order Spirochaetales Outcome Parents Paresthesia Patients Peptides Post Treatment Lyme Disease Syndrome Prognosis Publishing Questionnaires Recovery Reporting Research Research Institute Role Serology Skin Sleep Disorders Surveys Symptoms Syndrome System Testing Tick-Borne Diseases Tick-Borne Infections Time United States Work antibody detection biobank clinical database daily functioning erythema migrans expectation experience family management pathogen recruit response sleep difficulty tick-borne pathogen tool treatment response

项目摘要

Tickborne diseases are a serious health threat that has steadily risen, with reported cases more than doubling from 2004 to 2016. Lyme disease, or Lyme borreliosis, accounts for more than 80% of the reported cases of tickborne diseases in the US. It is estimated that over 476,000 cases of Lyme disease are diagnosed and treated per year in the US, and almost 130,000 cases are reported annually from European countries with surveillance for the infection. Our current work addresses the following areas in Lyme disease: development of new tests and biomarkers for infection, investigation of persistence of infection with B. burgdorferi in humans, and investigation of the role of immune response in Lyme disease and post treatment Lyme disease syndrome (PTLDS). We have three clinical protocols exploring diverse aspects of Lyme disease and tickborne infections that are currently open to recruitment. In these, and past clinical studies, we have evaluated more than 800 patients. Together with this large clinical database, we have assembled a large biorepository that has served to explore multiple avenues of research in Lyme borreliosis and tickborne diseases. In the past, we have published our collaborative study with Childrens National Research Institute, which showed that most parents of children diagnosed with Lyme disease reported that their kids recovered within six months of completing antibiotic treatment. The study collected survey responses from the parents of 102 children ages 5 to 18 years who had been diagnosed with Lyme disease between six months and 10 years before enrollment. Adolescents ages 10 to 18 years old were also invited to complete adolescent-specific questionnaires. According to these parent survey responses, 75% of children fully recovered within six months of completing treatment: 31% of all children recovered within one month; 30% recovered in one-to-three months; and 14% recovered in four-to-six months. Approximately 22% of children in the study experienced at least one symptom that persisted six or more months after completing treatment; of those, 9% had symptoms classified as post-treatment Lyme disease syndrome. Six percent of the children were not fully recovered at the time of the survey, with 1% experiencing symptoms significant enough to impair daily functioning. This study supports previous data showing an excellent overall prognosis for children with Lyme disease and can help clinicians manage families expectations about the varying post-treatment recovery times of pediatric Lyme disease patients. Post-treatment Lyme disease symptoms remains poorly understood in children and adults, and more research is needed to better understand these prolonged symptoms and identify treatment targets. We have also help study the serologic response to Anaplasma phagocytophilum and Babesia microti, two emerging tick-borne pathogens in the United States. Using a peptide array to select sets of linear peptides, we identified peptides that can be a useful tool for detection of antibody reactivity to both pathogens.

蜱传疾病是一种严重的健康威胁，而且一直在稳步上升，从2004年到2016年，报告的病例增加了一倍多。莱姆病或莱姆病疏螺旋体病占美国蜱传疾病报告病例的80%以上。据估计，美国每年诊断和治疗莱姆病病例超过476，000例，欧洲国家每年报告近130，000例，并对感染进行监测。我们目前的工作涉及莱姆病的以下领域：开发新的感染检测和生物标志物，调查B感染的持续性。本研究旨在研究莱姆病和治疗后莱姆病综合征（PTLDS）中免疫应答的作用。我们有三个临床方案，探索莱姆病和蜱传感染的各个方面，目前正在招募。在这些和过去的临床研究中，我们评估了800多名患者。与这个大型临床数据库一起，我们已经组装了一个大型生物储存库，用于探索莱姆病和蜱传疾病的多种研究途径。在过去，我们已经发表了我们与儿童国家研究所的合作研究，该研究表明，大多数被诊断患有莱姆病的儿童的父母报告说，他们的孩子在完成抗生素治疗后六个月内康复。该研究收集了102名5至18岁儿童的父母的调查答复，这些儿童在入学前6个月至10年被诊断患有莱姆病。还邀请10至18岁的青少年填写针对性的调查问卷。根据这些家长调查的答复，75%的儿童在完成治疗后6个月内完全康复：31%的儿童在1个月内康复; 30%在1至3个月内康复; 14%在4至6个月内康复。研究中大约22%的儿童在完成治疗后至少有一种症状持续6个月或更长时间;其中9%的儿童有治疗后莱姆病综合征的症状。6%的儿童在调查时没有完全康复，1%的儿童出现了严重的症状，足以影响日常功能。这项研究支持了先前的数据，这些数据显示莱姆病儿童的总体预后良好，并可以帮助临床医生管理家庭对儿童莱姆病患者不同治疗后恢复时间的期望。治疗后莱姆病症状在儿童和成人中仍然知之甚少，需要更多的研究来更好地了解这些长期症状并确定治疗目标。我们还帮助研究了对嗜吞噬细胞无浆体和微小巴氏杆菌的血清学反应，这是美国两种新出现的蜱传病原体。使用肽阵列来选择线性肽组，我们鉴定了可以是用于检测对两种病原体的抗体反应性的有用工具的肽。

项目成果

期刊论文数量（24）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Pediatric Lyme disease: systematic assessment of post-treatment symptoms and quality of life.

儿科莱姆病：治疗后症状和生活质量的系统评估。

DOI：
10.1038/s41390-023-02577-3
发表时间：
2023
期刊：
Pediatric research
影响因子：
3.6
作者：
Monaghan,Maureen;Norman,Stephanie;Gierdalski,Marcin;Marques,Adriana;Bost,JamesE;DeBiasi,RobertaL
通讯作者：
DeBiasi,RobertaL

Natural killer cell counts are not different between patients with post-Lyme disease syndrome and controls.

莱姆病后综合征患者和对照组之间的自然杀伤细胞计数没有差异。